SPECIAL REPORT
MOST SHARED
- Obama Sees Strains Unless US, China Balance Growth
- Can Apple Top Microsoft as Most Valuable Tech Firm?
- European Commission Objects to Sun Micro-Oracle Deal
- Future of Marketing
- Mad Mail: Buy the Berkshire Hathaway Split?
- Cramer: 5 Stocks to Play the Next Bull Run
- JPMorgan Lifts Salary Freeze Amid Recovery
- Framed for Porn – By a PC Virus
- Israel: Leader of Business Innovation
- Maria's Market Message
- Why Google is Paying $750 Million for Ad Mob
- Warren Buffett to Sell Stakes In Union Pacific & Norfolk Southern
- Nov. 9: Unusual Volume Leaders
- The Battered Businesses Behind Housing
- Modern Warfare 2's Record-Breaking Launch
- Merck’s Mega-Monday Morning
- Why are Traders Bullish on This Food Company?
- Profiting From Natural Gas: Strategists
- S&P Stocks Trading at New 52-Week Highs
- Yahoo Is in Expanding Mode, Hiring: CEO
- UK Most at Risk of Losing Top Credit Rating: Fitch
- New Lows for Stocks Next Year: Equities Bear
- GM CEO Starts Charm Tour at Opel in Germany
- Vodafone Extends Cost-Cutting Scheme, Hits Targets
- Bad Debt Weighs on Barclays Earnings
- HSBC Operating Profit Beats, US Bad Debts Slip
- Fed's Tarullo Backs Surcharges to Limit Bank Size
- Look Ahead: 'Risk On' Sentiment Could Fuel Rally Further
RSS FEED
Pharma's Market
Pharma's Market Comments: |

Since there should really be no compelling reason to blog or report on Dendreon [DNDN
Loading...
()
] and Provenge for quite awhile, here's one last hurrah. Someone named Lindy writes, "The obvious manipulation of this stock...makes me ill!" And Jack Truman thinks I'm partially to blame for that. He says, "(You) have been pumping all along...you should be ashamed of yourself...you guys have been pumping this pile of crap right into the ground."
My post yesterday on the contrast between press releases from Roche and Genentech [DNA
Loading...
()
] about the very same thing drew a couple of comments from readers who disagreed with me. Spencer Guthrie who has an Elan [ELN
Loading...
()
] email address and says he used to work at Genentech writes, "When you read those PRs (press releases), Roche's is written for the laymen, and Genentech's is written for the medical community. I think Genentech always takes the more scientific approach and that's why they have been so successful."
And an anonymous e-mailer says, "I really enjoy some of your insightful commentary/articles, however sometimes you take things to an absurd level. The Genentech/Biogen-Idec press release wasn't that difficult to interpret for investors and the medical community and perhaps the common lay person who is actually interested in treatment options...." DNA, by the way, kicks off the biopharma earnings season after the closing bell next Tuesday.
And my entry about Barack Obama's campaign getting a million bucks from the pharmaceuticals/health products industries prompted Neal Breitenbach to write, "I work for Pfizer and have given probably $1,000 to Obama's campaign (including the primary). I am certainly NOT (the caps are his) contributing to the Obama campaign because I work for big Pharma. I may or may not be affected by Obama policies as a Pharma employee, but will definitely be better off as a citizen with Obama as my President."
Neal's boss, Pfizer [PFE
Loading...
()
]Chairman and CEO Jeff Kindler, was a fairly frequent contributor to Senator Hillary Clinton's campaign. According to the Center for Responsive Politics, Kindler gave the maximum $2,300 to Clinton three times since April of last year. His name does not come up when you search Kindlers who have contributed to Obama.
I'll be off for Yom Kippur and won't be blogging tomorrow. Before the holiday starts, though, I'll be seeing another hand specialist this afternoon because one month after my klutzy BlackBerry-related injury my finger is still very swollen, sore and inflexible. I'm not whining, just updating for anyone who cares or who might appreciate my cautionary tale about the dangers of walking and BlackBerrying. I still catch myself doing it and have to force myself to stand still.
Questions? Comments?









